Johnson & Johnson is in talks to acquire Texas-based biotech startup Ollin Biosciences for up to $3.4 billion, including $2.2 billion in upfront cash and $1.2 billion in potential milestone payments. The deal would provide Johnson & Johnson entry into retinal disease therapies via Ollin's lead phase-three drug candidate, OLN324, which targets wet age-related macular degeneration and diabetic macular edema. The acquisition follows J&J's recent multi-billion dollar buyouts of Firefly Bio and Intra-Cellular Therapies amid record biotech deal volumes in 2026.
Acquisition terms and deal structure
- ▪Johnson & Johnson is in discussions to acquire privately held Texas-based drug developer Ollin Biosciences for up to $3.4 billion
- ▪Johnson & Johnson could announce the acquisition of Ollin Biosciences as early as November 16, 2026, though people familiar with the matter cautioned talks could still collapse
- ▪Under proposed terms, Johnson & Johnson would pay Ollin Biosciences' backers $2.2 billion in upfront cash and up to $1.2 billion in potential future milestone payments
Ollin Biosciences drug pipeline and funding
- ▪Ollin Biosciences raised $330 million in June 2026 to fund late-stage clinical trials for its experimental drug OLN324
- ▪Ollin Biosciences is backed by investment firms Arch Venture Partners, Mubadala Capital, TCGX, RA Capital, and Monograph Capital
- ▪Ollin Biosciences' lead experimental drug, OLN324, is being developed to treat wet age-related macular degeneration and diabetic macular edema
Biotech industry M&A trends in 2026
- ▪According to investment bank Stifel, a record 46 biotech companies valued at over $1 billion have been acquired so far in 2026, surpassing the prior annual record of 35
- ▪Biotechnology sector dealmaking reached $131.5 billion in the first half of 2026 before slowing to $44.8 billion in the second half of the year to date
Other recent Johnson & Johnson acquisitions
- ▪Johnson & Johnson purchased psychiatric drugmaker Intra-Cellular Therapies for $14.6 billion at the start of 2025 to expand its neurological disorder business
- ▪Johnson & Johnson acquired oncology drug developer Firefly Bio earlier in 2026 in a transaction valued at $1 billion in cash
Expansion into eye disease treatments
- ▪Acquiring Ollin Biosciences would give Johnson & Johnson entry into retinal disease treatments, an area where the drugmaker currently has limited presence despite its contact lens business
- ▪Pharmaceutical companies including Merck and Bayer have expanded into eye disease medicines in recent years by buying early-stage companies
Story comments
Loading comments…